Allergen immunotherapy for allergic asthma: The future seems bright
Language English Country England, Great Britain Media print-electronic
Document type Review, Journal Article
PubMed
36702170
DOI
10.1016/j.rmed.2023.107125
PII: S0954-6111(23)00013-6
Knihovny.cz E-resources
- Keywords
- Allergen immunotherapy, Asthma, Clinical effectiveness, Disease modification, Disease remission, Mechanisms, Prevention,
- MeSH
- Allergens MeSH
- Rhinitis, Allergic * drug therapy MeSH
- Antigens, Dermatophagoides therapeutic use MeSH
- Asthma * etiology MeSH
- Desensitization, Immunologic MeSH
- Humans MeSH
- Pollen MeSH
- Pyroglyphidae MeSH
- Sublingual Immunotherapy * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Allergens MeSH
- Antigens, Dermatophagoides MeSH
Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.
References provided by Crossref.org
EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
